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Abstract
Background: Epidemiological observations suggest that cancer arises from chronically inflamed
tissues. Inflammatory bowel disease (IBD) is a typical example as patients with longstanding IBD are
at an increased risk for developing colorectal cancer (CRC) and mutations of the NOD2/CARD15
gene increase the risk for Crohn's disease (CD). Recently, NOD2/CARD15 has been associated with
a risk for CRC in some studies, which stemmed from ethnically diverse populations. Our aim was
to identify common NOD2/CARD15 mutations in Hungarian patients with sporadic CRC.
Methods: A total of 194 sporadic CRC patients (m/f: 108/86, age at diagnosis of CRC: 63.2 ± 9.1
years old) and 200 healthy subjects were included. DNA was screened for SNP8, SNP12 and SNP13
NOD2/CARD15 mutations by denaturing-HPLC and confirmed by direct sequencing.
Results: NOD2/CARD15 mutations were found in 28 patients (14.4%) and in 23 controls (11.5%, p
= NS). Allele frequencies for SNP8/R702W (1.8% vs. 1.5%) SNP12/G908R (1.8% vs. 1.8%) and
SNP13/3020insC (3.6% vs. 2.5%) were also not statistically different between patients and controls.
The clinicopathologic characteristics of CRC patients with or without NOD2/CARD15 mutations
were not significantly different.
Conclusion: Our results suggest that common NOD2/CARD15 mutations alone do not contribute
to CRC risk in the Hungarian population.
Background
Colorectal adenocarcinoma (CRC) is the second most
common cause of death in developed countries. It is pre-
ceded only by lung cancer in mortality statistics as the
leading cause of malignant deaths. Approximately
700,000 new cases are discovered and almost half a mil-
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CRC mortality has almost tripled in the past four decades,
with a great proportion of the patients being diagnosed
only in advanced stages [2]. The pathogenesis of sporadic
CRCs is thought to be multifactorial, with multiple
genetic and various environmental factors involved [3-5].
Epidemiological studies have suggested that chronic con-
tinuous inflammation predisposes to cancer [6]. A typical
example is the association between inflammatory bowel
diseases (IBD) and colorectal cancer (CRC) [7]. Although
CRC, complicating ulcerative colitis and Crohn's disease,
accounts for only 1–2% of all cases of CRC in the general
population, it is considered a serious complication of the
disease accounting for 1 in 6 of all deaths in IBD patients
[8,9]. Precursor lesions of CRC may often have inflamma-
tory histological features [10]. Inflammation may favour
tumorigenesis by inducing DNA damage [11] stimulating
continuous cell proliferation or apoptosis [12] and stimu-
lating angiogenesis.
Assuming that the underlying chronic inflammation in
IBD may be implicated in the progression of CRC, genetic
factors, known to be involved in the chronic inflamma-
tory process in ulcerative colitis and Crohn's disease, may
simultaneously hasten the development of CRC in IBD
patients. Several studies have shown that NOD2/CARD15,
a gene that overlaps with the IBD1 locus on chromosome
16q12, is significantly associated with susceptibility to
IBD [13]. The physiological role of the CARD15/NOD2
protein remains under detailed examination. It is a cyto-
plasmic protein expressed in peripheral blood monocytes,
Paneth cells and intestinal epithelial cells, and is structur-
ally related to the well-described R proteins in plants,
which mediate host resistance to microbial pathogens
[14]. Variant alleles result in altered NF-κB activity
[15,16]. Variant NOD2/CARD15 alleles are also associ-
ated with reduced α-defensin secretion from Paneth cells
in response to bacteria [17]. Finally, NOD2/CARD15 was
found to be involved in the regulation of TLR2 [18] and
carriers of the variant alleles exhibited increased intestinal
permeability [19].
Two single-nucleotide polymorphisms of NOD2/CARD15
(SNP8: R702W and SNP12: G908R) and a frameshift
mutation (SNP13: 3020insC) were shown by independent
groups to be associated with susceptibility to CD [20,21].
The presence of one variant allele increases the risk of
developing CD 1.5–4.3-fold, and of two copies by up to
20–40-fold [22,23], yet rates are lower in Northern
Europe [24].
Recently, NOD2/CARD15 was found to increase the risk
for colorectal cancer (CRC). Kurzawski et al. [25] found
that the presence of 3020insC mutation increased the risk
of developing CRC by 2.23-fold in Polish patients with an
older average age at diagnosis. This was however not con-
firmed in a Finnish study by Alhopuro et al. [26]. Note-
worthy, in the most recent Greek study, all three common
variants were found to be associated with an increased risk
for CRC (OR: 2.4–5.2) [27].
In light of these findings, and given that the frequency of
the mutations varies in different populations, our aim was
to investigate the presence of the three common NOD2/
CARD15 variants in a large cohort of patients with spo-
radic CRC in Hungary, a country with a high CRC inci-
dence rate, comparable to that observed in Poland.
Methods
One hundred and ninety-four consecutive Caucasian
patients with sporadic CRC were investigated (male/
female: 108/86, age at diagnosis of CRC: 63.2 ± 9.1 years
old). All patients with known hereditary cancer syn-
dromes and previous diagnosis of IBD or a positive family
history of CRC were excluded. The clinical data, symp-
toms (hematochezia, weight loss, anemia, changes in
bowel movement habits) and clinicopathologic character-
istics of the patients are shown in Table 2.
The control group for mutation analysis consisted of 200
gender-matched healthy Caucasian subjects (male/
female: 102/98), without any known gastrointestinal dis-
ease. Also colorectal cancer was absent in the family his-
tory of controls [23]. The study was approved by the
Semmelweis University Regional and Institutional Com-
mittee of Science and Research Ethics. Each patient was
informed on the nature of the study and signed the
informed consent form.
Detection of NOD2/CARD15 SNP8, SNP12 and 13 
mutations
Genomic DNA was isolated from whole blood according
to the QIAamp DNA blood mini kit (QIAGEN GmbH,
Germany). Each exon was amplified by PCR using previ-
ously published primer sequences [23]. The initial dena-
turation step (at 94°C for 7 min) was necessary in order
to activate the AmpliTaq Gold (Applied Biosystems, Fos-
ter City, CA, USA), followed by 33 cycles (at 94°C for 20
s, at 61°C for 30 s, at 72°C for 25 s) with a final extension
step at 72°C for 7 min. Then, denaturing high-perform-
ance liquid chromatography (dHPLC, wave DNA frag-
ment analysis system, Transgenomic Limited, UK) was
performed to analyze the exons. In the final step, PCR
products were denatured at 94°C for 5 min to induce het-
eroduplex formation during the subsequent step of slowly
cooling down to room temperature, over thirty minutes.
Five microliters of these PCR products was then automat-
ically loaded onto the DNASep cartridge (Transgenomic
Limited, UK) in the wave system. The specific acetonitrilePage 2 of 5
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WaveMaker 3.4.4 software. The particular run tempera-
ture for the detection of each SNP was determined using
positive controls, which were kindly provided by Dirk
Seegert from Kiel, Germany.
Finally, when a sequence variation was observed in the
dHPLC profile, the relevant PCR product was sequenced
on both strands to confirm the alteration. Sequencing
reactions were performed with the ABI BigDye terminator
cycle sequencing kit v1.1 (Applied Biosystems, Foster
City, CA, USA) and samples were sequenced on an ABI
Prism 310 genetic analyzer (Applied Biosystems, Foster
City, CA, USA).
Statistical analysis
Variables were tested for normality by Shapiro Wilk's W
test. T-test with separate variance estimates, χ2-test and χ2-
test with Yates correction were used to test differences
between patients with CRC and controls, as well as within
subgroups of CRC patients. Odds ratios (OR) and logistic
regression were calculated to compare genetic and clinical
data. A p value < 0.05 was considered statistically signifi-
cant. For the statistical analysis, SPSS12.0 (SPSS Inc, Chi-
cago, IL, USA) was used with the help of a statistician (Dr.
Peter Vargha).
Results
A large number of CRC patients were diagnosed at an
advanced stage (T stage III-IV: 76.2%) and with clinical
symptoms (57.7%) as shown in Table 2. NOD2/CARD15
mutations were found in 28 patients (14.4%) and in 23
controls (11.5%, p = 0.45, OR: 1.29 (95%CI: 0.72–2.34).
Allele frequencies for SNP8/R702W (1.8% vs 1.5%),
SNP12/G908R (1.8% vs. 1.8%) and SNP13/3020insC
(3.6% vs. 2.5%) were also not statistically different
between CRC patients and controls (see Table 1). All
patients and controls were heterozygous for a particular
mutation, no homozygous or compound heterozygous
carriers were identified.
There was no difference between the age at diagnosis in
the group of patients harboring at least one mutation
(mean age 64.5 ± 7.9 years old) compared to the patients
without the mutations (mean age 63.0 ± 9.3 years old).
Furthermore, the CARD15/NOD2 variants carrier status
was not associated with any of the examined clinico-
pathologic variables (Table 2).
Discussion
Contrary to previous reports, in the present study we were
unable to detect an association between the prevalence of
common NOD2/CARD15 mutations and the risk for spo-
radic CRC in a Hungarian population. Comparable vari-
ant allele frequencies were observed in both, the patient
and control groups.
A possible explanation for the differences between the
previous studies and the present one may be the differ-
ences in carrier frequencies among the controls. An asso-
ciation between NOD2/CARD15 was initially reported by
a Polish study in 2004 [25]. The incidence of CRC in
Poland is high, similar to Hungary. An association
between the 3020insC mutation and the risk for CRC (OR:
2.23) was reported in 250 Polish CRC patients older than
50 years, at the time of time diagnosis. The carrier fre-
quency was 14.4% in this subgroup of patients, however,
it was only 7% in controls. This was not confirmed in
patients who were younger than 50 years, at the time of
diagnosis or in patients with HNPCC or a family history
of CRC. In addition, no other common NOD2/CARD15
mutations were examined in the study.
In contrast, no association was found between the above
mutation and the risk for CRC cases with or without fam-
ily history in 926 CRC cases analyzed in a Finnish study.
We have to note though, that the carrier (3.7%) as well as
allele frequencies (1.9%) for both CRC patients and con-
trols was lower in the Finnish study compared to the pre-
vious study as well as the present one. Variant allele
frequencies in Finland (which by language is related to
Table 1: NOD2/CARD15 SNP8, 12 and 13 in patients with sporadic colorectal cancer (CRC) and (CD) and controls
R702W (SNP8) G908R (SNP 12) 3020insC (SNP 13)
CRC n (%) Controls n (%) CRC n (%) controls n (%) CRC n (%) controls n (%)
Wild type 187 (96.4) 194 (97.0) 187 (96.4) 193 (96.5) 180 (92.8) 190 (95.0)
All Carriers 7 (3.6) 6 (3.0) 7 (3.6) 7 (3.5) 14 (7.2) 10 (5.0)
Heterozygous 7 (3.6) 6 (3.0) 7 (3.6) 7 (3.5) 14 (7.2) 10 (5.0)
Allele frequency 7 (1.8) 6 (1.5) 7 (1.8) 7 (1.8) 14 (3.6) 10 (2.5)
P value for 
carriers
0.78 0.95 0.40
ORcarrier (95%CI) 1.21 (0.39–3.67) 1.03 (0.35–3.00) 1.48 (0.64–3.41)Page 3 of 5
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in IBD patients [24]. The prevalence of R702W, G908R
and 3020insC was 3.3%, 0.6% and 4.8%, respectively, in
the Finnish IBD study (in controls it was 1.8%, 0 and
1.7%) with only 3020insC being more common in CD
compared to controls. Noteworthy, unlike in the Polish
study in the study by Alhopuro et al., [26] patients with an
age older than 50 years at diagnosis did not have an
increased frequency of 3020insC mutation (4.3%) com-
pared to patients with an age <50 years at the time of CRC
diagnosis. In addition, no differences in the variant
NOD2/CARD15 alleles were found between with any clin-
ico-pathological characteristics.
The more recent study, from Greece, reported an associa-
tion between all three common NOD2/CARD15 variants
and the risk for sporadic CRC in 104 consecutive patients
and 100 controls. Carrier frequencies in CRC patients
were surprisingly high; 23% for 3020insC, 9.6% for
R702W and 13% for G908R compared to much lower
rates in the controls (12%, 2% and 7%, respectively). In
addition, carrier rates in CRC patients were comparable to
the rates previously reported in Greek IBD patients [28].
Nonetheless, variant allele frequencies were much higher
compared to the present study. In the most recent study by
Roberts et al [29], not only SNP8 (OR: 2.3) were associ-
ated with the risk of sporadic CRC but also the presence of
any common variant alleles (OR:2.8, 95%CI: 1.5–5.4). In
addition, two homozygous SNP8 carriers were detected in
the CRC patient group. Male gender was associated to the
carriage of variant allele.
In concordance with a previous report from Finland [26],
we did not find any association between clinicopatholog-
ical characteristics or the location of the CRC and the pres-
ence of NOD2/CARD15 variants. In contrast, in the Greek
study [27], an association was found between the TNM
stage at diagnosis and the presence of the variant NOD2/
CARD15 allele. NOD2/CARD15 variant alleles were asso-
ciated with a more advanced TNM stage; however, partly
due to the small number of patients, results were not cor-
rected for other possible confounding factors (e.g. age at
diagnosis or tumor differentiation). Finally, we have to
note that according to previously published data (Polish-
Greek study) a patient number of between 175–280
would be necessary to detect the reported association with
a type I error of 0.05 and a type II error of 0.10, thus the
present study had enough statistical power to detect the
above differences in NOD2/CARD15 polymorphisms if
present.
Conclusion
In summary, common NOD2/CARD15 mutations were
not associated with disease susceptibility for sporadic
CRC in a Hungarian population. This, in concordance
with previous reports, suggests that it is unlikely that
NOD2/CARD15 mutations alone are responsible for the
development of sporadic CRC.
Table 2: Clinicopathologic characteristics of colorectal cancer patients (CRC) with respect to the presence or absence of NOD2/
CARD15 mutations
Total (n = 194) Carrier (n = 28) Non-carrier (n = 166)
Male/female 108/86 17/11 91/75
Age at diagnosis (years) 63.2 ± 9.1 64.5 ± 7.9 63.0 ± 9.3
Age
≤60 years 63 9 54
>60 years 131 19 112
Symptoms at diagnosis*
Yes 112 20 92
No 82 8 74
Tumor location
Rectum 83 6 77
Left-colon 73 15 58
Right colon 38 7 31
T stage
1 6 2 4
2 40 6 34
3 113 15 98
4 35 5 30
N stage#
0 63 8 55
1 or 2 86 10 76
*symptoms: hematochezia, weight loss, anemia, changes in bowel movement habits
# data available in 149 patients
p = not significant, by κ2 or T-test with separate variance estimates as appropriatePage 4 of 5
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